Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial

What Was Tested

Researchers studied Liraglutide in the context of psoriasis and psoriatic arthritis in this randomized controlled trial publication.

There were some clinical studies on GLP-1R agonist liraglutide therapy for psoriasis patients with type 2 diabetes, but there is a lack of randomized controlled trials and the mechanism of which remains unclear.

Who Took Part

The abstract describes 25 patients taking part.

A total of 25 psoriasis patients with type 2 diabetes were randomized 1: 1 divided into the control group (n = 13) or liraglutide group (n = 12) for 12 weeks.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The methods mention a period of 12 weeks.

The researchers determined the PASI, the DLQI, histopathology of psoriasis skin, and the expression of IL-17, IL-23, and TNF-α in the psoriasis skin.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Interleukin-17, Interleukin-23, Liraglutide, Psoriasis, Tumor Necrosis Factor-alpha and Glucagon-Like Peptide-1 Receptor Agonists.

The authors tagged it with the keywords type 2 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized study of Liraglutide in 25 patients in people with psoriasis and psoriatic arthritis over 12 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (The Journal of dermatological treatment), a journal based in England.

More context: the Liraglutide compound page, Psoriasis and psoriatic arthritis research.